RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
20 déc. 2018 07h00 HE
|
Helsinn Healthcare S.A.
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
20 déc. 2018 02h45 HE
|
Helsinn Healthcare S.A.
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
12 déc. 2018 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
03 déc. 2018 12h30 HE
|
Helsinn Healthcare S.A.
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO,...
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
27 nov. 2018 10h52 HE
|
Helsinn Healthcare S.A.
The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients LUGANO, SWITZERLAND, AND NEW YORK, NY,...
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
06 nov. 2018 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group strengthens the Board with the appointment of Francesco Granata
01 oct. 2018 05h05 HE
|
Helsinn Healthcare S.A.
Helsinn Group strengthens the Board with the appointment of Francesco Granata LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting
26 sept. 2018 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting Lugano, Switzerland, September 26, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
31 juil. 2018 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...
Helsinn: Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)
10 juil. 2018 04h11 HE
|
Helsinn Healthcare S.A.
Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV) ...